Author: Anoma Ranaweera, Medical Writer, Auckland, New Zealand; Chief Editor: Dr Amanda Oakley, Dermatologist, Hamilton, New Zealand, March 2015.

In January 2015, the US Food and Drug Administration (FDA) approved secukinumab (Cosentyx™, Novartis, USA) for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy (a drug that is absorbed into the bloodstream and distributed to all parts of the body, eg methotrexate, acitretin or ciclosporin) or phototherapy (light therapy).

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for secukinumab. It was classified as prescription medicine by Medsafe New Zealand in August 2015.

Secukinumab is very effective in the treatment of severe psoriasis and acts fast. It appears very safe. However, only small numbers of patients have been treated to date (March 2015).

How does secukinumab work?

How is secukinumab administered?

Dosage modifications

Warnings and precautions

Link to key clinical-trial evidence about secukinumab

Potential drug interactions with secukinumab

What are the adverse effects of secukinumab?

In clinical trials the following adverse events have been observed at an incidence >2%:

Use of secukinumab in pregnancy

Use of secukinumab in nursing mothers

Paediatric use of secukinumab

Geriatric use of secukinumab

New Zealand approved datasheets are the official source of information for these prescription medicines, including approved uses and risk information. Check the individual New Zealand datasheet on the Medsafe website.

Related information

Email Newsletter

Would you like to receive DermNet updates by email?

Submit your images

We're seeking high-quality photos of skin diseases.  


Skin lesion photography

Watch Dr Amanda Oakley presenting "Skin lesion photography" at The Australasian Skin Cancer Congress.

Subscribe to our mailing list

* indicates required
DermNet NZ Newsletter